Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

NCT: NCT05524324 · COMPLETED

NCT IDNCT05524324
StatusCOMPLETED
Start Date2022-11-15
Completion2026-04-24
SponsorAssistance Publique - Hôpitaux de Paris (OTHER)
First posted
Last updated

Brief Summary

The main objective of RIGHT-CRT is to assess the impact/efficacy of CRT on functional capacity in ACHD patients with SRV.

Frequently Asked Questions

What is Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT?

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT is a clinical trial registered under NCT05524324. Current status: COMPLETED.

What is the status of NCT05524324?

The current status of NCT05524324 (Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT) is: COMPLETED.

When did Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT start?

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT started on 2022-11-15.

Related Devices

PMA P240028Leadless Cardiac Resynchronization Therapy (CRT)EBR Systems, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑